TELA Bio (TELA)
NASDAQ:TELA
Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.74
$0.04(1.41%)
At close: 4:00 PM EST
$0.74
$0.04(1.41%)
Day’s Range― - ―
52-Week Range$0.50 - $2.20
Previous CloseN/A
Volume34.27K
Average Volume (3M)90.44K
Market Cap
$35.86M
Enterprise Value$55.31M
Total Cash (Recent Filing)$39.54M
Total Debt (Recent Filing)$56.39M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 12, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding44,766,148
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue0.68
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$2.00Price Target Upside170.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$86.71M
Bulls Say, Bears Say
Bulls Say
Revenue MomentumSustained multi-year revenue growth indicates broadening adoption of TELA's reinforced tissue matrices and deeper account penetration. Durable top-line momentum supports scale benefits, increases negotiating leverage with hospitals, and underpins a plausible path to improved operating leverage as fixed costs spread.
Strong Gross MarginsHigh, stable gross margins reflect favorable product economics for OviTex and related offerings, enabling margin retention as volumes scale. Durable manufacturing and pricing characteristics provide a structural cushion for profitability improvement as commercial productivity rises and SG&A absorption improves.
Product & Commercial ExpansionA fully staffed salesforce plus the new fully resorbable OviTex LTR broaden the addressable market and accelerate surgeon adoption. Structural commercial capacity and meaningful product innovation increase the odds of durable unit growth and international transferability of clinical value propositions.
Bears Say
Negative Equity & LeverageNegative equity and meaningful debt weaken financial flexibility and increase dependence on external funding. Over the medium term this elevates refinancing and covenant risk, constrains strategic optionality, and makes the company more sensitive to financing market conditions if operating cash flow doesn't improve.
Persistent Cash BurnSustained negative operating and free cash flow implies the business is not yet self-funding growth. Continued burn requires access to capital or higher leverage, which can dilute shareholders or increase interest costs, and constrains the company's ability to invest opportunistically without clear path to breakeven.
Nasdaq Listing RiskA formal deficiency notice introduces a structural listing and governance risk that can impair liquidity and investor confidence. Potential transfer to a lower-tier market or delisting would raise financing costs and complicate future equity raises, making execution of the commercialization plan more difficult.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $2.20 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $35.86M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Aug 12, 2026 which is in 51 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on May 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.17.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,766,148 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.00 (170.27% Upside)
$2.00 (170.27% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
-1344.47%
Trailing 12-Months
Asset Growth
-9.53%
Trailing 12-Months
Company Description
TELA Bio
Operating as a commercial-stage medical technology firm, TELA Bio, Inc. is dedicated to improving patient outcomes through advanced soft-tissue reconstruction solutions. Their approach emphasizes the preservation and restoration of the body's natural anatomy. The company offers a diverse portfolio of specialized products, including their flagship OviTex Reinforced Tissue Matrix, extensively utilized for hernia repair and abdominal wall reconstruction. Additionally, OviTex PRS Reinforced Tissue Matrix products cater to specific requirements within plastic and reconstructive surgery, addressing current gaps in treatment. They also provide a specialized OviTex variant designed for laparoscopic and robotic procedures. This sterile, reinforced tissue matrix is derived from ovine rumen and strengthened with polypropylene fiber, specifically engineered for use in minimally invasive hernia repairs. TELA Bio distributes its offerings primarily within the United States, utilizing a dedicated direct sales team. Established in 2012, TELA Bio, Inc. is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed constructive early progress with multiple meaningful positives: fully staffed U.S. commercial team, a major product launch (OviTex LTR), strong international performance (+41% in Europe), 16% unit growth, growing clinical evidence, and a board refresh to support scaling. These highlights were balanced against near-term financial pressures — modest 3% revenue growth in Q1, gross margin compression, a slightly wider net loss driven by higher interest expense, PRS utilization volatility due to concentration risk, and execution/timing risks tied to rep maturation and contract timing. Management expects an inflection in productivity as new hires reach the 6-month mark and reiterated at least 8% full-year revenue growth, signaling confidence in a stronger back half. Overall, the narrative is of early validation and building momentum, but with clear execution risks to realize the projected ramp.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$2.00
▲(170.27% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
20.74% Insiders
4.91% Mutual Funds
50.68% Other Institutional Investors
20.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---